Roche's Avastin stiff-armed by NICE again; Pfizer wins Japanese OK for Xeljanz;

 @FiercePharma: Pfizer tuberculosis drug hits FDA shortage list, with other TB remedies already scarce. Story | Follow @FiercePharma

 @EricPFierce: Momenta's Kaundinya doesn't mind some regulatory chaos in biosimilars. It allows industry to help shape pathway. Special Report | Follow @EricPFierce

> Roche's ($RHHBY) Avastin was again rebuffed by the U.K.'s cost-effectiveness watchdogs as a treatment for ovarian cancer. Report

> Pfizer ($PFE) won Japanese approval for its new rheumatoid arthritis drug Xeljanz, which got the FDA's thumbs up in November. Report

> Actavis won FDA approval for its version of the Reckitt Benckiser opioid dependency drug Suboxone, despite the branded maker's attempts to block it. Report

> Johnson & Johnson ($JNJ) recalled 1.9 million blood-sugar meters after a patient died after an inaccurate reading. Report

> Novartis ($NVS) sold its chemo-toxicity fighter Cardioxane to Clinigen, which believes it can revitalize the drug, for $33 million. Report

> South Africa's Cipla Medpro said its fiscal year earnings dropped 32%, despite a 30% increase in revenue to R2,297 billion, or about $248 million. Report

Medical Device News

 @FierceMedDev: Merck IUD lot hit with Hong Kong recall. Report | Follow @FierceMedDev

 @MarkHFierce: A multi-gene sequencing cancer Dx test is hitting the U.K. health system, thanks to the NHS. More | Follow @MarkHFierce

 @DamianFierce: Researchers at the Cleveland Clinic are developing a breath-based diagnostic to detect heart failure. Story | Follow @DamianFierce

> PrimeraDx teams with Quest for companion diagnostics. More

> TriReme allies with major China distributor for PAD devices. Story

> J&J recalls LifeScan glucose meters over shutdown risk. Report

Biotech News

 @FierceBiotech: From FierceBiotechResearch.com: Researchers find possible cause of neuron dysfunction in Alzheimers. Article | Follow @FierceBiotech

 @JohnCFierce: Another one bites the dust: Phytopharm slashes staff, scouts buyers after Parkinson's drug failure. Story | Follow @JohnCFierce

 @RyanMFierce: The top 10 moneymakers in Pharma, ordered by revenue and described in context: More | Follow @RyanMFierce

> PRACS' CRO implosion leaves a Who's Who of biopharma creditors in its wake. Story

> Headed into PhIII, Lundbeck scores $825M Alzheimer's drug pact with Otsuka. Report

> Ziopharm sharpens budget ax after cancer drug palifosfamide flops in PhIII. News

Pharma Manufacturing News

> FDA fast-tracks plant for injectable on shortage list. More

> India state ups effort to root out counterfeits. Story

> Form 483 lays out latest issues dragging down Hospira. Report

> Sanofi, Transgene split cost of specialized manufacturing. Article

> Actavis puts $40M into Florida plant. More

Biotech Research News

 @EmilyMFierce: Could a canker sore treatment be the next weight-loss drug? More | Follow @EmilyMFierce

> UMD scientists test new bird flu vaccine in animals. Report

> Astellas strikes deals to hunt for dengue fever therapies. More

> New database could be a boon for genomics research. Story

> Tiny wireless sensor moves brain research forward. Item

And Finally... Tufts University microbiologists identified the resistance mechanisms E. coli use to defy carbapenem antibiotics. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.